![](https://endpts.com/wp-content/uploads/2017/06/stencil.twitter-post-215.png)
With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope
The European venture group Medicxi is staking out some new terrain in biotech investing. And they’re bringing in two big players — Novartis and Google’s Verily …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.